Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trans-Guggulsterone (also known as E-guggulsterone) is a naturally occurring phytosteroid and stereoisomer of guggulsterone, isolated from the oleo-gum resin of the guggul tree (*Commiphora mukul* or *Commiphora wightii*). It acts as an antagonist of the farnesoid X receptor (FXR) and has been investigated for its potential hypolipidemic, anti-inflammatory, and anticancer properties. Unlike its cis-isomer (Z-guggulsterone), which primarily inhibits the IKK/NF-κB pathway, trans-guggulsterone has been shown to inhibit the MAPK/AP-1 signaling pathway, leading to the downregulation of matrix metalloproteinase-9 (MMP-9) expression and the suppression of cancer cell invasion, particularly in breast cancer models. It is widely used as a research reagent and is also found as a component of guggul-based dietary supplements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on trans-guggulsterone.